Aminocyclohexyl ether compounds and uses thereof

a technology of cyclohexyl ether and compounds, which is applied in the direction of biocide, drug compositions, cardiovascular disorders, etc., can solve the problems that antiarrhythmic compounds may actually increase mortality in patients who have had a myocardial infarction, and no satisfactory pharmacotherapy for the treatment and/or prevention of ventricular fibrillation during acute,

Inactive Publication Date: 2007-05-03
CARDIOME PHARMA CORP
View PDF40 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0067] In one version, the compounds of the present invention may be used to treat and / or prevent arrhythmia, atrial arrhythmia, ventricular arrhythmia, atrial fibrillation, ventricular fibrillation, atrial flutter, or ventricular flutter; in another version the compounds may be used to treat arrhythmia, atrial arrhythmia, ventricular arrhythmia, atrial fibrillation, ventricular fibrillation, atrial flutter, or ventricular flutter; in another version the compounds may be used to prevent arrhythmia, atrial arrhythmia, ventricular arrhythmia, atrial fibrillation, ventricular fibrillation, atrial flutter, or ventricular flutter.
[0068] In other embodiments, the present invention provides a composition or medicament containing an amount of one or more compounds of the present invention such as those according to formula (IA), (IB), (IC), (ID), or (IE), or a solvate, pharmaceutically acceptable salt, ester, amide, complex, chelate, stereoisomer, stereoisomeric mixture, geometric isomer, crystalline or amorphous form, metabolite, metabolic precursor or prodrug thereof, including isolated enantiomeric, diastereomeric and geometric isomers thereof, and mixtures thereof as described above, effective to produce analgesia or local anesthesia in a warm-blooded animal in need thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.

Problems solved by technology

At present, there is no satisfactory pharmacotherapy for the treatment and / or prevention of ventricular fibrillation during acute ischemia.
In fact, many Class I antiarrhythmic compounds may actually increase mortality in patients who have had a myocardial infarction.
However, drug therapy is often limited by adverse effects, including the possibility of increased mortality, and inadequate efficacy (Feld G. K., Circulation.
Conversion rates for these drugs range between 30-50% for recent onset AF (Capucci A., Aschieri D., Villani G. Q., Drugs &Aging 13(1):51-70, 1998), and they are also associated with a risk of the induction of Torsades de Pointes ventricular tachyarrhythmias.
Such events are particularly tragic in the case of AF as this arrhythmia is rarely a fatal in and of itself.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Aminocyclohexyl ether compounds and uses thereof
  • Aminocyclohexyl ether compounds and uses thereof
  • Aminocyclohexyl ether compounds and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

(1R,2R)-2-[(3R)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)cyclohexane monohydrochloride (Compound 1)

The reaction scheme for the preparation of compound 1 described herein is illustrated in FIG. 1.

[0888] Preparation of Intermediates

N-tert-Butoxycarbonyl-3R-pyrrolidinol (1R)

[0889] To a cold (0° C.) stirred solution of (R)-3-pyrrolidinol (20.6 g, 236 mmol; Omega cat. # HP-2113) in anhydrous THF (800 mL) was added dropwise a solution of di-tert-butyldicarbonate (56.7 g, 260 mmol, Aldrich cat. # 20,524-9) in THF (200 mL), and the resultant solution was stirred at room temperature for 18 h. Concentration in vacuo of the reaction mixture and short-path distillation in vacuo of the clear yellow residue gave 1R (42 g, 95% yield) as clear and colourless oil, which crystallized on standing.

[0890] Characterization: Rf 0.58 (CHCl3-MeOH, 4:1, v / v), 1H NMR (200 MHz, CDCl3) δ 4.4 (br s, 1H), 3.5-3.2 (m, 4H), 2.5 (br s, 1H), 2.0-1.9 (m, 2H), 1.4 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 154.7, ...

example 2

(1S,2S)-2-[(3R)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)cyclohexane monohydrochloride (Compound 2)

[0947] 5SSR, (1S,2S)-2-[(3R)-benzyloxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)cyclohexane was prepared and resolved according to Example 1. Compound 2 was then obtained from 5SSR using the procedure described above in example 1 with respect to the preparation of Compound 1.

[0948] Characterization: Calcd for C20H31NO4.HCl: C, 62.24; H, 8.36; N, 3.63. Found: C, 62.20; H, 8.46; N, 3.55. [α]D+26.690 (c 13.04 g / L, CHCl3)

example 3

(1R,2R) / (1S,2S)-2-[(3R) / (3S)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane monohydrochloride (Compound 3)

Preparation of Intermediates

[0949] N-Benzyloxycarbonyl-3-pyrrolidinol (1b). To a cold (−60° C.) solution of 1a (20.0 g, 225 mmol) and Et3N (79 mL, 560 mmol) in CH2Cl2 (200 mL) was added dropwise a solution of benzyl chloroformate (34 mL, 225 mmol) in CH2Cl2 (80 mL). After the addition was completed within 45 min, the reaction mixture (a yellow suspension) was allowed to warm up to room temperature and was stirred under argon at room temperature overnight. The reaction mixture was then quenched with 1M HCl aq (350 mL) and the organic layer was collected. The acidic aqueous layer was extracted with CH2Cl2 (2×150 mL) and the combined organic layers were dried. Evaporation in vacuo of the solvent provided 59.6 g of pale yellow oil, which was further pumped under high vacuum for 15 min to yield 58.2 g (17% over theoretical yield) of 1b suitable for the next step witho...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

Aminocyclohexyl ether compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses uses for the compounds and compositions, including the treatment of arrhythmia.

Description

TECHNICAL FIELD [0001] The present invention is directed to aminocyclohexyl ether compounds, pharmaceutical compositions, and processes for the synthesis of the aminocyclohexyl ether compounds, and therapeutic uses thereof. BACKGROUND OF THE INVENTION [0002] Ion channels are ubiquitous membrane proteins in the cells of warm-blooded animals such as mammals. Their critical physiological roles include control of the electrical potential across the membrane, mediation of ionic and fluid balance, facilitation of neuromuscular and neuronal transmission, rapid transmembrane signal transduction, and regulation of secretion and contractility. [0003] For example, cardiac ion channels are proteins that reside in the cell membrane and control the electrical activity of cardiac tissue. In response to external stimuli, such as changes in potential across the cell membrane, these ion channels can form a pore through the cell membrane, and allow movement of specific ions into or out of the cell. Th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/4015C07D207/02A61K31/40A61K31/455A61K31/4965A61K31/519A61P9/06C07D207/12
CPCA61K31/40A61K31/455C07D207/12A61K31/519A61K31/4965A61P43/00A61P9/00A61P9/06
Inventor BARRETT, G.M.CHOI, LEWISCHOU, DOUGHJUNG, GRACEPLOUVIER, BERTRANDLIU, YUZHONGZHU, JEFFSHENG, TAO
Owner CARDIOME PHARMA CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap